Andrew D. Goodman
University of Rochester Medical Center
Internal medicineSurgeryPathologyPsychologyVirologyRandomized controlled trialPhysical therapyImmunologyPlaceboIbudilastGlatiramer acetateDiseaseCentral nervous system diseaseMultiple sclerosisProgressive multifocal leukoencephalopathyExpanded Disability Status ScaleNatalizumabIn patientClinical trialPreferred walking speedMedicineBiologyPhysical medicine and rehabilitation
Publications 141
#1Dejan Jakimovski (UB: University at Buffalo)H-Index: 19
#2Katelyn Kavak (UB: University at Buffalo)H-Index: 7
Last. Robert Zivadinov (UB: University at Buffalo)H-Index: 85
view all 11 authors...
Abstract null null Background null . Multiple sclerosis (MS) patients with stable disease course might view continued treatment as unnecessary. However, guidelines regarding treatment discontinuation are currently lacking. null null null Objective null . To assess the clinical course after treatment discontinuation in MS patients with long disease duration. null null null Methods null . Patients who discontinued disease-modifying treatments (DMTs) and not resume treatment (n=216) were extracted ...
#1Hesham Abboud (University Hospitals of Cleveland)H-Index: 12
#2Andrea Salazar-Camelo (JHUSOM: Johns Hopkins University School of Medicine)H-Index: 3
Last. Andrew D. Goodman (URMC: University of Rochester Medical Center)H-Index: 55
view all 7 authors...
Neuromyelitis optica spectrum disorders (NMOSD) are a group of autoimmune inflammatory conditions that primarily target the optic nerves, spinal cord, brainstem, and occasionally the cerebrum. NMOSD is characterized by recurrent attacks of visual, motor, and/or sensory dysfunction that often result in severe neurological deficits. In recent years, there has been a significant progress in relapse treatment and prevention but the residual disability per attack remains high. Although symptomatic an...
#5Aaron E. Miller (ISMMS: Icahn School of Medicine at Mount Sinai)H-Index: 27
Background:ADS-5102, a delayed-release, extended-release (DR/ER) amantadine, improved walking speed in MS in a Phase 2 trial.Objective:The aim of this study was to present primary results of a Phas...
#1Robert A. Bermel (Cleveland Clinic)H-Index: 26
#2Janel Fedler (UI: University of Iowa)H-Index: 3
Last. Robert J. Fox (Cleveland Clinic)H-Index: 55
view all 15 authors...
Background:The SPRINT-MS trial demonstrated benefit of ibudilast on brain atrophy over 96 weeks in progressive multiple sclerosis (MS). Optical coherence tomography (OCT) was performed in all trial...
#5David T. DexterH-Index: 29
#1Seth N Levin (Columbia University)H-Index: 3
#2Shruthi Venkatesh (University of Pittsburgh)H-Index: 1
Last. Kaho B. Onomichi (Columbia University)H-Index: 3
view all 26 authors...
OBJECTIVE: To report initial results of a planned multicenter year-long prospective study examining the risk and impact of COVID-19 among persons with neuroinflammatory disorders (NID), particularly multiple sclerosis (MS). METHODS: In April 2020, we deployed online questionnaires to individuals in their home environment to assess the prevalence and potential risk factors of suspected COVID-19 in persons with NID (PwNID) and change in their neurological care. RESULTS: Our cohort included 1115 pa...
#5David T. DexterH-Index: 29
Sharing clinical trial data can provide value to research participants and communities by accelerating the development of new knowledge and therapies as investigators merge data sets to conduct new analyses, reproduce published findings to raise standards for original research, and learn from the work of others to generate new research questions. Nonprofit funders, including disease advocacy and patient-focused organizations, play a pivotal role in the promotion and implementation of data sharin...
#1Robert J. Fox (Cleveland Clinic)H-Index: 55
#2Paola Raska (Cleveland Clinic)H-Index: 3
Last. Jens Kuhle (University Hospital of Basel)H-Index: 65
view all 12 authors...
BACKGROUND Sensitive and specific biomarkers for use in progressive multiple sclerosis (MS) have not been established. We investigate neurofilament light (NfL) as a treatment response biomarker in progressive MS. OBJECTIVE To evaluate whether ibudilast 100 mg/day alters serum and cerebrospinal fluid (CSF) levels of NfL in progressive MS. METHODS In a protocol-defined exploratory analysis from a 2-year, phase 2 clinical trial of ibudilast in progressive MS (NCT01982942), serum samples were collec...
OBJECTIVE Determine whether a treatment effect of ibudilast on brain atrophy rate differs between participants with primary (PPMS) and secondary (SPMS) progressive multiple sclerosis. BACKGROUND Progressive forms of MS are both associated with continuous disability progression. Whether PPMS and SPMS differ in treatment response remains unknown. DESIGN/METHODS SPRINT-MS was a randomized, placebo-controlled 96-week phase 2 trial in both PPMS (n = 134) and SPMS (n = 121) patients. The effect of PPM...
#2Nick Hogan (University of Texas at Austin)H-Index: 1
Last. Teresa C. FrohmanH-Index: 37
view all 18 authors...
The patient is a right-handed White woman with relapsing-remitting MS diagnosed subsequent to left acute optic neuritis (AON). She described a previous transient episode of severe, electrical, and paroxysmal facial pain consistent with trigeminal neuralgia. Initial MRI demonstrated supratentorial
This website uses cookies.
We use cookies to improve your online experience. By continuing to use our website we assume you agree to the placement of these cookies.
To learn more, you can find in our Privacy Policy.